Furthermore, clinical data from FIDELITY support a potential role for MR antagonism in the prevention of lung inflammation, as the incidence of pneumonia was lower with finerenone vs. placebo in patients with CKD and T2D [22]. This evidence concerns the gene NR3C2 and type 2 diabetes mellitus.